A Patient-centric Case-based Approach for Pharmacists
A patient has been prescribed a biosimilar for RA.
HOW DO YOU DISCUSS THIS NEW TREATMENT?
Faculty and Video Experts
- Dr. Alan Low
- Mr. Aaron Sihota
- Mr. Gabriel Torani
- Ms. Carolyn Whiskin
Special Collaboration Video Expert
Denis Choquette, MD, Rheumatologist
Learning Objectives
After attending this session, participants will be able to:
- Describe the process by which biosimilars are approved and regulated by Health Canada
- Explain key data on biosimilars used in rheumatology
- Apply experiences and practical tips provided by experts to improve communication with patients on the use of biosimilars
- Use the acquired knowledge to educate patients and address their questions on the use of biosimilars with confidence
CCCEP File No. 1177-2018-2619-I-P
The Canadian Council on Continuing Education in Pharmacy has accredited this program for 1.5 CEUs.